COVID‐19 and kidney transplantation: Results from the TANGO International Transplant Consortium

7/10 Late treatment study

Cravedi et al., American Journal of Transplantation, doi:10.1111/ajt.16185 (Peer Reviewed)
COVID‐19 and kidney transplantation: Results from the TANGO International Transplant Consortium

Source PDF Share Tweet

Analysis of 144 hospitalized kidney transplant patients showing HCQ mortality HR 1.53, p = 0.17. Subject to confounding by indication.

Cravedi et al., 7/10/2020, retrospective, USA, North America, peer-reviewed, mean age 60.0, 25 authors.

risk of death, 53.0% higher, RR 1.53, p = 0.17, treatment 36 of 101 (35.6%), control 10 of 43 (23.3%).

This study is excluded in meta analysis: substantial unadjusted confounding by indication likely.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.

All 344 studies Meta Analysis

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit